Greenland Mines Ltd (NASDAQ: GRML) announced that IP Australia has granted Australian Patent No. 2023252508, covering gene therapy technology exclusively licensed by the company’s Biotech Division for the treatment of neuromuscular diseases through expression of the human Klotho protein. The patent strengthens the intellectual property supporting Greenland Mines’ Klotho-based therapeutic platform and includes claims covering gene therapy constructs, neuronal and induced pluripotent stem cells, and viral and non-viral delivery systems.
The company said the patent further supports development of its KLTO-202 program targeting amyotrophic lateral sclerosis (“ALS”) and other neuromuscular disorders. This development is significant as it provides broader IP protection for the company's gene therapy approach, potentially accelerating the path to clinical trials and eventual commercialization.
For the full press release, visit https://nnw.fm/PVbbH.
Greenland Mines Ltd is a Nasdaq-listed company with two operating divisions: Mining, focused on the exploration and development of the Skaergaard Project in southeast Greenland and, subject to closing of the previously announced transaction, the Sarfartoq neodymium-praseodymium (Nd-Pr) rare earths project in southwest Greenland; and Biotech, including Klotho’s KLTO‑202 primary indication for ALS. The company’s strategy is centered on building a multi-asset platform with exposure to rare earth magnet materials, precious metals and selected midstream processing opportunities, while advancing its broader North Atlantic Critical Metals Corridor vision linking Greenland resources with allied downstream jurisdictions and industrial infrastructure.
The grant of this Australian patent is a key milestone for Greenland Mines' biotech division, as it expands the geographic scope of its intellectual property portfolio. With ALS being a devastating neuromuscular disease with limited treatment options, the KLTO-202 program could address a significant unmet medical need. The patent's coverage of various delivery systems and cell types also provides flexibility in developing the therapy.
For the latest news and updates relating to GRML, visit the company’s newsroom at https://nnw.fm/GRML.
